Halozyme Therapeutics, Inc. (NASDAQ:HALO) is reporting second quarter financial results on Monday 10th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, HALO is expected to report 2Q20 income of $ 0.25 per share from revenue of $ 66.68 million.
For the full year, analysts anticipate top line of $ 234.80 million, while looking forward to income of $ 0.77 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 230.00 million ~ $ 245.00 million, where as bottomline are predicted in a range of $ 0.60 ~ $ 0.75 per share
Click Here For More Historical Outlooks Of Halozyme Therapeutics, Inc.
Previous Quarter Performance
Halozyme Therapeutics, Inc. announced loss for the first quarter of $ 0.04 per share, from the revenue of $ 25.35 million. The quarterly revenues declined 55.49 percent compared with the same quarter last year. According to street consensus, HALO was expected to report 1Q20 loss of $ 0.02 per share from revenue of $ 42.96 million. The bottom line results missed street analysts by $ 0.02 or 100 percent, at the same time, top line results fell short of analysts by $ 17.61 million or 40.99 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Halozyme Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of HALO was $ 28.97, representing a 127.93 % increase from the 52 week low of $ 12.71 and a 2.26 % decrease over the 52 week high of $ 29.64.
The company has a market capital of $ 3.93 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”HALO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 1st July 2020, initiated by Benchmark at Buy rating, with $ 39.00 target price.
- On 15th June 2020, maintained by Citigroup at Neutral rating, with $ 26.00 target price.
Conference Call
Halozyme Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.halozyme.com
Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The companys products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
